Bayer Suspends Trayslol at Health Canada's Request

At the request of Health Canada, the manufacturer Bayer Inc. has temporarily suspended marketing of the drug Trasylol (aprotinin), an anti-bleeding drug, pending a review of preliminary results from a clinical trial (the BART study) that suggested an increased risk of death.

Bayer Inc. will work with Health Canada so that the drug can be made available to certain patients in cases where the doctor believes the potential benefit clearly outweighs the risk.
Source: Health Canada